SB02024 is a novel highly potent, selective, ATP competitive, orally active inhibitor of vacuolar protein sorting 34 (Vps34) with Kd of 1 nM, >1000 times selective towards other PI3K isoenzymes; SB02024 is also highly selective at 1 uM in the DiscoveRx ScanMax panel of 468 kinases; reduces the number of GFP-2xFYVE puncta with IC50 of 14 nM, induces a dose-dependent increase in levels of NCOA4 and p62; blocks autophagy in vitro and reduces xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7; also significantly potentiates cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro.

SB-258585 is a potent, selective and orally active 5-HT6 receptor antagonist with Ki of 8.9 nM, >160-fold selectivity over other 5-HT receptor subtypes.

SB269652 is a potent, selective, negative allosteric modulator of dopamine D2 and D3 receptors, abolishes specific binding of [3H]nemanopride and [3H]spiperone to CHO-transfected D3 receptors with IC50 of1.86 and 0.18 nM.

SB271046 Hcl is a potent, selective and orally active 5-HT6 receptor antagonist with pKi of 8.9.

SB273005 is a potent integrin inhibitor with Ki of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.

SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.

SB-334867 is a selective non-peptide orexin OX1 receptor antagonist with a pKb value of 7.2.

SB-334867 is a selective orexin-1 (OX1) receptor antagonist.

SB-399885 is a potent, selective, brain penetrant 5-HT6 receptor antagonist with pKi of 9.11 and 9.02 for human recombinant and native 5-HT6 receptors.

SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively; exhibits 50-fold selectivity over OX2 receptor.

SB-435495 is a potent, orally active inhibitor of Lp-PLA2 with IC50 of 0.06 nM.

SB-612111 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor) antagonist with Ki of 0.33 nM.

SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd = 3.76 nM); exhibits 100-fold selectivity for OX1 over OX2 receptors.

SB-699393 is a potent, selective and CNS penetrant B-Raf inhibitor with Kd of 7.2 nM.

SB772077B (SB-772077B, SB77, SB-772077-B) is a potent, selective Rho kinase (ROCK) inhibitor with IC50 of 5.6 nM and 6.0 nM for ROCK1 and ROCK2, respectively.

SBE-β-CD (Sulfobutylether-β-Cyclodextrin; Captisol) is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs; Captisol is the trademark of SBE-β-CD registered by Ligand Pharmaceuticals.

SBI-425 (SBI425) is a potent, selective, orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor with IC50 of 16 nM, shows high selectivity over other alkaline phosphatases including IAP and PLAP.

SBI-477 is a chemical probe that coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes with EC50 of 100 nM and 1 uM, respectively.

SBI-993 is an analog of SBI-477 that shows improved potency and suitable pharmacokinetic properties for in vivo bioavailability

S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM, inhibits 5-oxo-ETE-induced calcium mobilization in human neutrophils..

S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM.

SC144 is an orally active small-molecule gp130 inhibitor.